U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Advisory Committees
  3. Committees and Meeting Materials
  4. Human Drug Advisory Committees
  5. Oncologic Drugs Advisory Committee
  6. Waiver for Conflicts of Interest for the June 21-22, 2017 Meeting of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (PedsODAC)
  1. Oncologic Drugs Advisory Committee

Waiver for Conflicts of Interest for the June 21-22, 2017 Meeting of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (PedsODAC)

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance

Disclaimer
The Food and Drug Administration Amendments Act of 2007 (FDAAA), enacted on September 27, 2007, added a new provision regarding financial conflicts of interest, § 712 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), effective October 1, 2007. Accordingly, for advisory committee meetings after October 1, 2007, FDA is granting waivers under 18 U.S.C. § 208 and § 712 of the FD&C Act, where applicable, when the relevant waiver standards in these statutes are met.

Waivers under 21 U.S.C. § 355(n)(4) were issued before October 1, 2007.  This provision was repealed, effective October 1, 2007, by the FDA.

Carola Arndt, M.D.

18 U.S.C. 208(b)(3) Waiver for the June 21-22, 2017 Meeting of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (PDF-243KB)

Disclosure Document for the June 21-22, 2017 Meeting of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (PDF-136KB)

Leo Mascarenhas, M.D.

18 U.S.C. 208(b)(3) Waiver for the June 22, 2017 Meeting of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (PDF-49KB)

Disclosure Document for the June 22, 2017 Meeting of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (PDF-14KB)

Alberto Pappo, M.D.

18 U.S.C. 208(b)(3) Waiver for the June 22, 2017 Meeting of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (PDF-107KB)

Disclosure Document for the June 22, 2017 Meeting of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (PDF-33KB)

Brenda Weigel, M.D.

18 U.S.C. 208(b)(3) Waiver for the June 22, 2017 Meeting of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (PDF-244KB)

Disclosure Document for the June 22, 2017 Meeting of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee (PDF-14KB)

Back to Top